Vivo Capital Fund VIII, L.P.'s Form 4 filing
Terns Pharmaceuticals, Inc.TERN · filed Aug 16, 2022
- Accession no.
- 0001213900-22-048763
- Filed
- Aug 16, 2022, 8:44 PM ET
- Trade date
- Aug 12-16, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market purchases total $6.98M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vivo Capital Fund VIII, L.P.CIK 0001618788 | 10% Owner |
| Vivo Capital VIII, LLCCIK 0001618789 | 10% Owner |
| Vivo Capital Surplus Fund VIII, L.P.CIK 0001628048 | 10% Owner |
| Vivo Opportunity, LLCCIK 0001728970 | 10% Owner |
| Vivo Opportunity Fund Holdings, L.P.CIK 0001930214 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 12, 2022 | Common Stock | PPurchaseAcquired | +1,123,021 | $2.98F2 | +$3,346,602.58 | 1,480,374 | Indirect | Duplicate filing |
| Aug 15, 2022 | Common Stock | PPurchaseAcquired | +1,218 | $2.99F3 | +$3,641.82 | 1,481,592 | Indirect | Duplicate filing |
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +1,500,000 | $2.42F4 | +$3,630,000 | 2,981,592 | Indirect | Duplicate filing |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +1,500,000 | $2.42 | +$3,629,850 | 1,500,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.83 to $3.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $2.96 to $3.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F4
The reporting person acquired 1,500,000 shares of Common Stock at $2.42 per share and 1,500,000 pre-funded warrants at $2.41990 per warrant in an underwritten offering.
Referenced by the price of 1 transaction in Table I.